整合性基因组学确定了阿尔茨海默氏症疾病中的APOE ε4因子
Herve Rhinn1, Ryousuke Fujita, Liang Qiang
1Department of Pathology, Columbia University, 650 W. 168th Street, New York, New York 10032, USA.
Nature
|July 26, 2013
概括
遗传因素,如APOE4和衰老影响阿尔茨海默氏症的风险. 这项研究确定了一种与APOE4相关的分子途径,影响了粉样蛋白前体蛋白代谢,这表明一种促进LOAD的机制.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 晚期阿尔茨海默氏病 (LOAD) 风险受到遗传因素的影响,特别是阿波利波蛋白E ε4等位基因 (APOE4),以及诸如衰老等非遗传因素.
- 了解将这些因素与LOAD病原体联系起来的分子机制对于开发有效干预措施至关重要.
研究的目的:
- 调查与APOE4载体状态和LOAD相关的转录组变化.
- 确定参与受APOE4和LOAD影响的分子通路的核心调节媒介.
- 探索已识别的介质在粉样前体蛋白 (APP) 代谢和LOAD发作的作用.
主要方法:
- 从未受影响的APOE4载体和LOAD患者的全转录组大脑皮层基因表达数据的分析.
- 差异同表达相关性网络分析以确定候选监管调解者.
- 研究候选基因中的遗传变异及其对粉样蛋白沉积和LOAD发病年龄的影响.
主要成果:
- APOE4 载体状态表现出与 LOAD 相似的转录形状.
- 网络分析确定了几种候选调解物,包括APBA2,FYN,RNF219和SV2A,参与APP代谢.
- 发现RNF219的一个遗传变异会影响粉样蛋白沉积和LOAD发病年龄.
结论:
- 一个与APOE4相关的分子通路与APP代谢有关,有助于LOAD的致病性.
- 这些发现突出了减轻LOAD风险和进展的潜在治疗目标.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.4K
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
1.7K
相关概念视频
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
01:29Pharmacogenomics: Identification of New Drug Targets
129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
01:29Alzheimer Disease l: Introduction
38
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
38
01:23Alzheimer Disease ll: Pathophysiology
44
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
44